Related references
Note: Only part of the references are listed.cIMPACT-NOW update 7: advancing the molecular classification of ependymal tumors
David W. Ellison et al.
BRAIN PATHOLOGY (2020)
High levelMYCNamplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma
Mark Raffeld et al.
ACTA NEUROPATHOLOGICA COMMUNICATIONS (2020)
Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT
Gabrielle Truitt et al.
JOURNAL OF NEURO-ONCOLOGY (2019)
MYCN amplification drives an aggressive form of spinal ependymoma
David R. Ghasemi et al.
ACTA NEUROPATHOLOGICA (2019)
EANO guidelines for the diagnosis and treatment of ependymal tumors
Roberta Ruda et al.
NEURO-ONCOLOGY (2018)
Outcomes After Reirradiation for Recurrent Pediatric Intracranial Ependymoma
Derek S. Tsang et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2018)
Epidermal growth factor receptor overexpression is common and not correlated to gene copy number in ependymoma
Carsten Friedrich et al.
CHILDS NERVOUS SYSTEM (2016)
Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study
Roberta Ruda et al.
NEURO-ONCOLOGY (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups
Kristian W. Pajtler et al.
CANCER CELL (2015)
Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients
Elizabeth Vera-Bolanos et al.
NEURO-ONCOLOGY (2015)
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Reliability and validity of the M. D. Anderson Symptom Inventory Spine Tumor Module Clinical article
Terri S. Armstrong et al.
JOURNAL OF NEUROSURGERY-SPINE (2010)
New (alternative) temozolomide regimens for the treatment of glioma
Wolfgang Wick et al.
NEURO-ONCOLOGY (2009)
O6-Methylguanine-DNA-Methyltransferase in recurring anaplastic ependymomas: PCR and immunohistochemistry
A. M. Buccoliero et al.
JOURNAL OF CHEMOTHERAPY (2008)
Validation of the M.D. Anderson Symptom Inventory Brain Tumor Module (MDASI-BT)
T. S. Armstrong et al.
JOURNAL OF NEURO-ONCOLOGY (2006)
A case report of a recurrent intracranial ependymoma treated with temozolomide in remission 10 years after completing chemotherapy
S Rehman et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2006)
A multicenter retrospective study of chemotherapy for recurrent intracranial ependymal tumors in adults by the Gruppo Italiano Cooperativo di Neuro-Oncologia
AA Brandes et al.
CANCER (2005)
Is gross-total resection sufficient treatment for posterior fossa ependymomas?
L Rogers et al.
JOURNAL OF NEUROSURGERY (2005)
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules
AW Tolcher et al.
BRITISH JOURNAL OF CANCER (2003)
Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR/erbB2 and downstream Erk1/2 and AKT pathways
WL Xia et al.
ONCOGENE (2002)